Company Overview
Molbio Diagnostics Limited, a point-of-care diagnostics company, provides healthcare technologies to diagnose infectious and non-communicable diseases. It manufactures and sells chip based diagnostic devices, chips and reagents, X-ray equipment's, and single/dual detectors. It also offers disposable POCT devices, which includes dengue, malaria, and COVID-19 tests; Tabletop analysers, a portable machine that are used to perform molecular or immunodiagnostic tests to detect infectious diseases, such as tuberculosis, human papillomavrus, STIs, and GI disorders. In addition, the company offers Truenat, a multi-disease real-time polymerase chain reaction platform that enables treatment decisions for various infectious and non-communicable diseases, such as tuberculosis, human immunodeficiency virus, malaria, viral hepatitis, COVID-19, dengue, chikungunya, influenza, H1N1, HPV/cervical cancer, cholera, leprosy, etc.; and Truenat assays. The company was incorporated in 2000 and is based in Verna, India.
Why Investors Should Care
Return on capital employed stands at 16.5%.
Net profit has compounded at 7682.3% per year over the last five years.
Revenue has grown at a 63.7% CAGR over the past five years.
Operating margin of 18.5% supports profitability.
Carries low leverage with a debt-to-equity ratio of 0.38.
Recent Developments
- Mar 2026 Revenue of ₹1,414.96 Cr (+41.9% YoY); net profit ₹166.59 Cr.
- Trailing 12 Months Year-on-year growth — revenue +41.9%, earnings +14.8%.
- 5-Year Trend Long-term compounding — revenue CAGR 63.7%, profit CAGR 7682.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 63.72% |
| 1 Year: | 41.85% |
Compounded Profit Growth
| 5 Years: | 7,682.28% |
| 1 Year: | 14.81% |
Stock Price Performance
| 1 Year: | +11.40% |
| 6 Months: | - |
| 3 Months: | - |
| 1 Month: | - |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- RSI (14)78.32 · Overbought
P/E of 77.68 is above the sector median of 41.64 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 63.7% over 5 years.
- Profit CAGR of 7682.3% over 5 years.
CONS
- Trading at a high P/E of 77.7.
- RSI at 78 suggests overbought conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MOLBIO Molbio Diagnostics Limited NSEPHARMA | 1,160.50 | 77.68 | ₹12,989.85 Cr | 0.00% | 16.50% | 14.42% | 63.72% | 7,682.28% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,899.00 | 39.73 | ₹4.56 L Cr | 0.82% | 17.94% | 13.74% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 9,100.00 | 94.06 | ₹2.42 L Cr | 0.36% | 18.96% | 15.32% | 10.98% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,857.00 | 75.99 | ₹1.64 L Cr | 0.77% | 9.05% | 25.79% | 13.27% | 20.22% |
| 5 | APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA | 8,650.00 | 64.10 | ₹1.24 L Cr | 0.22% | 19.20% | 20.48% | 14.85% | 33.34% |
| 6 | LENSKART LENSKART SOLUTIONS LTD NIFTY_MIDNSEPHARMA | 684.90 | 236.17 | ₹1.19 L Cr | 0.00% | 7.21% | 5.65% | 35.38% | 66.99% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,120.00 | 22.36 | ₹1.13 L Cr | 0.09% | 19.04% | 18.59% | 16.55% | 36.99% |
| 8 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,385.00 | 28.85 | ₹1.12 L Cr | 0.88% | 14.86% | 11.27% | 7.23% | 11.45% |
| 9 | LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA | 1,840.00 | 111.85 | ₹99,333.61 Cr | 0.13% | 19.53% | 16.77% | 3.77% | 4.00% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue | 322.43 Cr | 819.73 Cr | 997.48 Cr | 1,414.96 Cr |
| Cost of Revenue | 145.58 Cr | 343.67 Cr | 417.29 Cr | 581.62 Cr |
| Gross Profit | 176.84 Cr | 476.06 Cr | 580.19 Cr | 833.34 Cr |
| Operating Expenses | 163.27 Cr | 261.71 Cr | 351.25 Cr | 553.95 Cr |
| Operating Income | 13.58 Cr | 214.35 Cr | 228.94 Cr | 279.39 Cr |
| EBITDA | 47.91 Cr | 184.34 Cr | 254.99 Cr | 326.17 Cr |
| Interest Expense | 6.65 Cr | 13.69 Cr | 16.01 Cr | 31.39 Cr |
| Pretax Income | 9.54 Cr | 129.64 Cr | 194.43 Cr | 231.14 Cr |
| Tax Provision | 12.98 Cr | 46.10 Cr | 55.85 Cr | 67.00 Cr |
| Net Income | -72.60 L | 101.95 Cr | 145.10 Cr | 166.59 Cr |
| Diluted EPS | - | - | - | - |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Total Assets | 1,034.21 Cr | 1,221.06 Cr | 1,461.56 Cr | 2,148.42 Cr |
| Current Assets | 616.74 Cr | 823.16 Cr | 929.83 Cr | 1,384.84 Cr |
| Cash & Equivalents | 6.97 Cr | 12.68 Cr | 114.75 Cr | 355.53 Cr |
| Inventory | 347.02 Cr | 315.14 Cr | 435.91 Cr | 449.26 Cr |
| Receivables | 188.75 Cr | 425.45 Cr | 271.66 Cr | 408.74 Cr |
| Total Liabilities | 296.87 Cr | 392.22 Cr | 494.27 Cr | 839.65 Cr |
| Current Liabilities | 257.55 Cr | 342.76 Cr | 441.67 Cr | 557.36 Cr |
| Long Term Debt | 98.50 L | 15.12 Cr | 6.14 Cr | 212.41 Cr |
| Total Debt | 118.53 Cr | 183.62 Cr | 146.93 Cr | 450.08 Cr |
| Total Equity | 721.48 Cr | 823.38 Cr | 968.39 Cr | 1,169.34 Cr |
| Shares Outstanding | - | - | - | - |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Operating Cash Flow | 64.13 Cr | 9.57 Cr | 287.10 Cr | 50.38 Cr |
| Investing Cash Flow | -39.73 Cr | -45.01 Cr | -122.65 Cr | -93.22 Cr |
| Financing Cash Flow | 18.24 Cr | -31.55 Cr | -26.15 Cr | 276.07 Cr |
| Capital Expenditure | -14.50 Cr | -16.11 Cr | -54.66 Cr | -50.02 Cr |
| Free Cash Flow | 49.63 Cr | -6.54 Cr | 232.44 Cr | 36.30 L |
| Net Change in Cash | 42.64 Cr | -66.99 Cr | 138.30 Cr | 233.23 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Gross Margin % | 54.8% | 58.1% | 58.2% | 58.9% |
| Operating Margin % | 4.2% | 26.1% | 23.0% | 19.7% |
| Net Margin % | -0.2% | 12.4% | 14.5% | 11.8% |
| ROE % | -0.1% | 12.4% | 15.0% | 14.2% |
| ROCE % | 1.7% | 24.4% | 22.4% | 17.6% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MOLBIO
Stocks to Watch Today: Rail Vikas Nigam, Cohance Lifesciences, Molbio Diagnostics, Purple Style Labs,... - Moneycontrol.com
<a href="https://news.google.com/rss/articles/CBMiygJBVV95cUxQbTlyLU9jS0tlTlpvcks1cWdkVXZjM1hYX1Q4NW1ucm5qTkpSRkxQWE5XNGplN2ZaTWttcXlNUjg0bEdRSXJhdEVXc3J6clJwZXpzZDJFWVhPLWYtS0FLVU4zbFJZMUpzYmxGN3FvVjltbFJKVHJ4MzFiUFkxSVY1RTI4NkRHSlhsaXY5N0…
Molbio Diagnostics Q1FY27 Results: Net profit up 523% YoY to ₹527.44 million - scanx.trade
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxORkd5eEtKQU1Cel9rMFNaNGNReWpqTjBrQUY5QW9iVUFNR1RLQ0FxM2lDWTQ5bmlucVdLQVhrWjE2LVgzYVRfNDljT19zcWdCZm5rekVpT0dLOGlta3NjWk5GcUlQaWU4QnRUUjJCYVp0ZEV0aWR5Mjk1TGxpQmJIelNzTFFqdEFkVlNOZH…
Newly-Listed Molbio Diagnostics Posts Rs 52.7 Cr Profit in Q1 - HDFC Sky
<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxPTWE1MExjUEdiZG1ENl8wTS1mWGtRTnE2WUNhcXRkT0o1ejI5WE9vSUNSNG1rSS1lRjB2RldlUTNEZF9meU5YYnBvWXU4Sy1Pb1MtR29RWXU0Q2FsamdNb2hXSmlPXzFUTzB1eEhrZWFpaUpyNko2R045bzA2V292a1JDQjBxOW5taFpYSH…
Molbio Diagnostics reports consolidated net profit of Rs 58.75 crore in the June 2026 quarter - Business Standard
<a href="https://news.google.com/rss/articles/CBMiiwJBVV95cUxOaDNPQWNqb2hUY1NnOHFqZ3lES00tdmpZaTFsSy05bnJQRGRKeEtIZTY3X1BxZDRwRlVOUlZBb3NoS2JFcVJqVGFlLV9NUFRILTN5M2N5Rm1FTDN5OEJGZUNRUkVVQ3p1ckNpY2laSWhMMDhhVnR5dmVENkRSWmFhRVJ4WGNlRFNNWVdUZ0…
Molbio Diagnostics IPO Listing Today: Check Expected Listing Price And Gain Based On Latest GMP - NDTV Profit
<a href="https://news.google.com/rss/articles/CBMi1AFBVV95cUxOYUJ6OFYtWmVCZHZ6R2xUdkRVRnJQbm1wX2drVzhwNDJ0WlNiZjVhX2t1M1ZESWdZb0pKYURGVXE0WVlxYkVqcXE0aGVSVmduT1JKaFJMZnJHelJIY1FXdUFKZFBxRDBSWndlNjd2MmpHX2wwU2FVNnkyWF80eVJDd0wxNTViSzUzVk5SaV…
Molbio Diagnostics shares rally 6% after strong debut. What should investors do? - The Economic Times
<a href="https://news.google.com/rss/articles/CBMi5gFBVV95cUxPMXNISURkYTQyRWlja0hBWm5RNjB4QTltZ0Fmb0ZzSFF1MmJrQkhWZGJlcGl4SFFaaTVVRlktSTBtcXRDTGtkWkdjaVBzU0FJb0V1QWNpNk9kNnh2NHVCTzJXU3ZNME5sZ19RU185cHJGOVZmNktLOUJKak9DY1ZVUEVnNnlwY2ZQcEF6V0…
MOLBIO — Frequently Asked Questions
What is the current share price of Molbio Diagnostics Limited (MOLBIO)?
As of 2026-09-08 04:53 IST, Molbio Diagnostics Limited (MOLBIO) trades at ₹1,160.50 on NSE. Its 52-week range is ₹1,036.65 to ₹1,238.85.
What is the market capitalisation of MOLBIO?
Molbio Diagnostics Limited (MOLBIO) has a market capitalisation of ₹12,989.85 Cr on NSE.
What is the P/E ratio of MOLBIO?
MOLBIO trades at a trailing price-to-earnings (P/E) ratio of 77.68. The industry average P/E is 41.64. Its price-to-book (P/B) ratio is 10.87.
What is the return on equity (ROE) of MOLBIO?
MOLBIO has a return on equity (ROE) of 14.42%. Its return on capital employed (ROCE) is 16.50%.
Is MOLBIO a good stock to buy?
This page provides a data-driven analysis of Molbio Diagnostics Limited (MOLBIO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.